Prelude Therapeutics Inc. has synthesized tyrosine-protein kinase JAK2 inhibitors reported to be useful for the treatment of cancer, myelofibrosis, essential thrombocythemia and graft-vs.-host disease.
Centauri Therapeutics Ltd. has disclosed conjugates consisting of a peptide such as polymyxin or its derivative covalently linked to a rhamnose unit via a linker reported to be useful for the treatment of infections.
Merck Sharp & Dohme LLC has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a GTPase KRAS G12D mutant-targeting moiety via a linker reported to be useful for the treatment of cancer.
Genome & Co. has divulged antibody-drug conjugates consisting of antibodies targeting basal cell adhesion molecules (BCAM) covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.
Uppthera Inc. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a serine/threonine-protein kinase PLK1 (STPK13)-targeting moiety reported to be useful for the treatment of cancer.
Arc Research Institute and Stanford University have disclosed ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) and/or ENPP3 inhibitors reported to be useful for the treatment of cancer.
Synnovation Therapeutics Inc. has described heterocyclic compounds acting as nuclear factor erythroid 2-related factor 2 (NFE2-related factor 2; NFE2L2; NRF2) inhibitors reported to be useful for the treatment of cancer.
RSS